Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Investor Presentation (February 2021)
24 slides from Iol Chemicals & Pharmaceuticals's investor presentation, February 2021
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Investor Presentation February 2021
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading APls / bulk drugs company and is a significant player in the field of specialty chemicals with world class facilities R&D Centre is approved by Department of Scientific and Industrial Research (DSIR) an
Slide 4: Key Highlights
Key Highlights Team size of 2,000+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 12 products in employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) pipeline company worldwide being in India with ~30% Global share backward integrated with ~
Slide 5: Professional Board of Directors backed by a Strong Team
Professional Board of Directors backed by a Strong Team Rajender Mohan Malla Vikas Gupta (Chairman and Independent Director) (Executive Director) He has very distinguished career of four decades. He had held He is academically equipped with the knowledge and possesses top and significant decision-ma
Slide 6: Our Journey
Our Journey Commenced Ethyl Production of Unit-01 Ibuprofen Incorporated 1991 Acetate 1998 Ibuprofen 2006 (Dedicated) Started acetic acid Commenced Acetic Co-Generation 1986 & Listing on BSE 1996 2000 2007 Anhydride Plant Unit-02 Ibuprofen Unit-06 (Dedicated) Pantoprazole Unit-03 Multi IBB, MCA and
Slide 7: Our Strong Global reach spread across 80 countries
Our Strong Global reach spread across 80 countries Argentina China Spain Netherlands Thailand Vietnam Bangladesh UAE Germany Nigeria Finland Uruguay Belgium Italy Indonesia Peru Switzerland UK Brazil Egypt Iran South Africa Portugal Kenya 7
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA Ibuprofen EUGMP Certification in Certificate of Suitability Certificate of Suitability facility since 2015, 2013, 2017 & from EDQM for IBUPROFEN, from EDQM for recertified in 2019 Recertification in 2020 CEP No. 316-2008 LAMOTRIGINE, CEP No. 066-2012
Slide 9: Business Segment – API
Business Segment – API Product wise Segmentation - Q3FY21 API Pipeline Gabapentin - Antiepileptic Losartan - Antihypertensive 47.9% Albendazole - Antiprotozoal Chemicals API 41% 59% Folic Acid – Dietary Supplement 5.9% Valsartan - Antihypertensive 0.8% 2.1% 2.3% Levetiracetam - Antiepileptic Product
Slide 10: Strong Customer base across Diversified Industries - API
Strong Customer base across Diversified Industries - API 10
Slide 11: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals Product wise Segmentation – Q3FY21 1 India’s Largest Ethyl Acetate plant at single location India’s second largest manufacturer for Iso Butyl 2 Benzene (IBB) with ~30% global share 32% API Chemicals Captive consumption of Mono Chloro Acetic Acid with 59% 41% 3
Slide 12: Strong Customer base across Diversified Industries – Specialty Chemicals
Strong Customer base across Diversified Industries – Specialty Chemicals 12
Slide 13: Manufacturing Facility spread across 92 acres at a Single Location
Manufacturing Facility spread across 92 acres at a Single Location with GMP approved guidelines API manufactured in batch manner and intermediates & Specialty chemicals in continuous product Research & Development 1 delivery manner based on DCS technology R&D work is carried out at the facility 2 24
Slide 14: Our Core Capabilities
Our Core Capabilities Strong Manpower Technology • Operations of the company are managed by qualified and experienced professionals • Blend skills of chemistry and engineering with latest tools & techniques for benchmarks achieved in API & Chemical products • Asia Pacific's first continuous dual tec
Slide 15: Location Benefits
Location Benefits Connectivity Single Site Location • Unit is well connected with State Highway • Company is enjoying economics of scale and National Highway • Pharmaceuticals segment is backward • Proximity to railway station and Dry port integrated with chemical segment and • Connected through roa
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars EHS Policy Economical & Social Responsibilities Environmental Responsibilities • Strive to minimize the adverse impact on • Assets and Capital Management & Utilization • State & central pollution control board & MoEF environment, health and Safety by upgrading • Custo
Slide 17: Key Financial Summary
Key Financial Summary Financial Summary Financial Summary (Q3FY21) (Q3FY20) 521 Total Income 515 Total Income Quarterly Summary 165 EBITDA 163 EBITDA (INR Cr) 115 PAT 98 PAT 17 All Profits and Total Income include Other Income
Slide 18: Financial Performance – Quarterly & 9MFY21
Financial Performance – Quarterly & 9MFY21 Revenues & Margins* – 9 Monthly & Quarterly Segmental Revenue Break-Up 2,000.0 50.0% Q3FY21 9MFY21 45.0% 45.9% 43.9% 43.8% 1,800.0 45.0% 1,600.0 1,524.7 40.0% 1,463.7 1,400.0 31.7% 32.7% 35.0% 31.7% 30.6% 1,200.0 30.0% 1,000.0 22.0% 24.2% 25.0% 37% 41% 19.0
Slide 19: Financial Performance - Annual
Financial Performance - Annual Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000.0 1,910.5 50.0% 50.0% Gross margin % 1,800.0 1,695.7 45.0% 44.3% 45.0% 44.3% 11.3% 1,600.0 40.0% 40.0% EBITDA % 1,400.0 32.9% 38.2% 35.0% 35.0% 32.9% 29.7% 30.9% 1,200.0 30.0% 30.0% 16.3% 24.8% 30.9%
Slide 20: Segmental Breakup - Annual
Segmental Breakup - Annual Product wise Segmentation* Geographical wise Segmentation 35.0% 66.0% 2020 2020 64.0% 34.0% 32.7% 61.6% 2019 2019 66.3% 38.4% 35.9% 64.4% 2018 2018 63.2% 35.6% 43.8% 68.0% 2017 2017 56.0% 32.0% Chemical Pharmaceutical Domestic Export 20 *excludes Unallocated Segmentation
Slide 21: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 Q3FY20 Q3FY21 9MFY20 9MFY21 Revenues 710.7 983.3 1,685.3 1,894.5 511.3 513.0 1,453.0 1,506.6 Other Income 1.3 6.3 10.4 16.0 4.0 7.8 10.7 18.1 Total Income 711.9 989.6 1,695.7 1,910.5 515.2 520.8 1,463.7 1,524.7 Cost o
Slide 22: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY18 FY19 FY20 H1FY21 Share Capital 56.2 56.9 56.9 58.7 Other Equity 159.5 417.5 756.7 1036.1 Shareholder's Funds 215.7 474.3 813.5 1094.8 Long Term Debt 258.1 189.9 0.0 0.0 Short Term Debt 135.3 67.7 55.9 21.4 Current Maturities 28.5 26.4 0.
Slide 23: Shareholder Information
Shareholder Information Stock Data (As on 15th February, 2021) Institutional Holders (%) Market Capitalization(₹) 3,869.8 Crs Stitching Depositary APG Emerging Markets Equity Pool 1.08% Face Value(₹) 10.0 Morgan Stanley Asia Pte 1.06% 52-Week High(₹) 898.9 Acadian Emerging Markets Small Cap Fund 1.0
Slide 24: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35 24
IOL Chemicals and Pharmaceuticals — Investor Presentation (February 2021) on 6ix